How should novel agents be used in the current treatment pathways for GvHD?

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate the question of how novel agents should be used in the current treatment pathways for GvHD. This recorded discussion was chaired by Amin Alousi, and featured Hildegard Greinix, Mohamad Mohty, Florent Malard, and Arnon Nagler.

Alousi begins the discussion by asking which approaches are commonly used by the steering committee members to sequence therapies for GvHD. Greinix mentions the challenge of working in Europe due ROCK inhibitors not yet being approved. The steering committee talk about the use of ruxolitinib and ibrutinib, as well as steroid tapering schedules. They also discuss when to describe GvHD as refractory and consider the impact of cumulative exposure to steroids.